What the FDA labels say about taking them together
Atropine and siponimod
Siponimod's FDA label of June 30, 2026 names atropine in its warnings and precautions section; the atropine labels PlainMeds reads (4) do not name siponimod.
Check it at the source: the atropine FDA label on DailyMed (effective May 18, 2026, Hospira, Inc.); the siponimod FDA label on DailyMed (effective June 30, 2026, Novartis Pharmaceuticals Corporation).
What does the atropine label say about siponimod?
Atropine's label (effective May 18, 2026) and its 3 other brand-application labels do not name siponimod in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Atropine Sulfate), Hospira, Inc., effective May 18, 2026 (SPL set ad8916e7-206e-409e-2582-30d072845dd4), via openFDA; the full label on DailyMed
What does the siponimod label say about atropine?
Siponimod label, warnings and precautionsThe conduction abnormalities typically were transient, asymptomatic, resolved within 24 hours, rarely required treatment with atropine, and did not require discontinuation of MAYZENT treatment.
Source: FDA drug label (MAYZENT), Novartis Pharmaceuticals Corporation, effective June 30, 2026 (SPL set 44492772-5aed-4627-bd85-e8e89f308bb3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atropine | Siponimod | |
|---|---|---|
| Labeled for | n/a | Multiple sclerosis |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $7.74 per mL 1% eye drops | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once